Association between -871C>T promoter polymorphism in the B-cell activating factor gene and the response to rituximab in rheumatoid arthritis patients

Rheumatology (United Kingdom)

Volumn 52, Issue 4, 2013, Pages 636-641

  Ruyssen Witrand, Adeline ^a   Rouanet, Stéphanie ^b   Combe, Bernard ^c   Dougados, Maxime ^d   Loët, Xavier Le ^e   Sibilia, Jean ^f   Tebib, Jacques ^g   Mariette, Xavier ^h   Constantin, Arnaud ^a  

^a UNIVERSITÉ PAUL SABATIER   (France)

^b Roche France   (France)

^c LAPEYRONIE HOSPITAL   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e ROUEN UNIVERSITY HOSPITAL   (France)

^f UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^g CENTRE HOSPITALIER LYON SUD   (France)

^h BICÊTRE HOSPITAL   (France)

Author keywords

Baff; Clinical response; Genetic polymorphism; Rheumatoid arthritis; Rituximab

Indexed keywords

B CELL ACTIVATING FACTOR; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; IMMUNOGLOBULIN; METHOTREXATE; RHEUMATOID FACTOR; RITUXIMAB;

ADULT; AGED; ALLELE; ARTICLE; DRUG CONTRAINDICATION; DRUG HYPERSENSITIVITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETREATMENT; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT FAILURE; TREATMENT RESPONSE;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; B-CELL ACTIVATING FACTOR; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME;

EID: 84875577862     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes344     Document Type: Article

References (16)

1. Cohen SB, Emery P, Greenwald MW et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793_806.
2. Nakajima K, Itoh K, Nagatani K et al. Expression of BAFF and BAFF-R in the synovial tissue of patients with rheumatoid arthritis. Scand J Rheumatol 2007;36:365_72.
3. Thien M, Phan TG, Gardam S et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004;20:785_98.
4. Novak AJ, Grote DM, Ziesmer SC et al. Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders. J Clin Oncol 2006;24: 983_7.
5. Gragnani L, Piluso A, Giannini C et al. Genetic determinants in hepatitis C virus-associated mixed cryoglobulinemia: role of polymorphic variants of BAFF promoter and Fcgamma receptors. Arthritis Rheum 2011;63:1446_51.
6. Gottenberg JE, Sellam J, Ittah M et al. No evidence for an association between the -871 T/C promoter polymorphism in the B-cell-activating factor gene and primary Sjogren's syndrome. Arthritis Res Ther 2006;8:R30.
7. Nossent JC, Lester S, Zahra D, Mackay CR, Rischmueller M. Polymorphism in the 50 regulatory region of the B-lymphocyte activating factor gene is associated with the Ro/La autoantibody response and serum BAFF levels in primary Sjogren's syndrome. Rheumatology 2008;47:1311_6.
8. Gottenberg JE, Miceli-Richard C, Ducot B et al. Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort. Arthritis Res Ther 2009;11: R114.
9. Kawasaki A, Tsuchiya N, Fukazawa T, Hashimoto H, Tokunaga K. Presence of four major haplotypes in human BCMA gene: lack of association with systemic lupus erythematosus and rheumatoid arthritis. Genes Immun 2001; 2:276_9.
10. Sellam J, Hendel-Chavez H, Rouanet S et al. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. Arthritis Rheum 2011;63: 933_8.
11. van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria thatinclude simplified joint counts. Arthritis Rheum 1998;41: 1845_50.
12. Nam JL, Winthrop KL, van Vollenhoven RF et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 2010;69:976_86.
13. Isaacs JD, Ferraccioli G. The need for personalised medicine for rheumatoid arthritis. Ann Rheum Dis 2011;70: 4_7.
14. Fabris M, Quartuccio L, Saracco M et al. BLyS promoter polymorphism and response to rituximab in rheumatoid arthritis (RA) patients positive or negative for the rheumatoid factor. Arthritis Rheum 2009;60:1678 (abstract).
15. Emmerich F, Bal G, Barakat A et al. High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura. Br J Haematol 2007;136:309_14.
16. Nardelli B, Belvedere O, Roschke V et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 2001;97:198_204.